Rhythm Biosciences Board Renewal and Composition Update

Rhythm Biosciences Ltd (ASX:RHY) has announced the appointment of Dr David Atkins as Managing Director, effective immediately. Additionally, Dr Trevor Lockett and Mr Lou Panaccio will retire from the Board at the 2024 Annual General Meeting, while Mr Otto Buttula is set to step down from the position of Chair before the end of CY'24. The company is also in ongoing discussions for potential new directors, including a new Chair.

Rhythm Chairman's Comments on Board Changes

As a Board, we are delighted to appoint David as Managing Director of the Company. Having observed David in the role of CEO since May, the Board has admired his leadership and team building skills, his strong and tireless commitment and tenacious approach to building out Rhythm's protected intellectual property portfolio. We believe David has displayed the right approach to rebuilding the Company and restoring shareholder value, initially through the impending launch of ColoSTAT® in what we believe to be a more robust and commercially attractive product offering. On behalf of the Company, whilst their retirement is not effective until the AGM, I would also like to gratefully acknowledge Dr Lockett and Mr Panaccio for their service and contribution to the Company since its' inception, both were instrumental in the early stages, respectively as technology advisor and professional ASX Board member, over the past 7 plus years. Despite retiring, Dr Lockett has offered to continue to provide support on an as required, consultancy basis. The Company wishes both Dr Lockett and Mr Panaccio well in their future endeavours.

Rhythm Biosciences Board Renewal and Composition Summary

Rhythm Biosciences Ltd (ASX:RHY) has made significant changes to its Board, appointing Dr David Atkins as Managing Director, while announcing the retirements of Dr Trevor Lockett and Mr Lou Panaccio from the Board, and Mr Otto Buttula's decision to step down from the position of Chair. The company is targeting the appointment of a new Chair before the end of CY'24. The Chairman expressed delight in appointing Dr Atkins and acknowledged the contributions of the retiring members. Rhythm Biosciences remains committed to its goal of delivering simple, affordable blood tests for the early detection of cancers, aiming to improve patient outcomes and reduce the global burden of cancer.